---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-25-000054"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T12:52:04.132034+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q1 2025 net loss improves to $41M; cash runway into H2 2026

## Summary
- Net loss of $41.0M ($0.65 loss per share) vs Q1 2024 loss of $52.2M ($0.84).
- Revenue $13.2M, up from $9.1M, driven by collaborative agreements and contract manufacturing; no product sales after MARGENZA sale.
- Cash, equivalents and marketable securities $154.1M as of Mar 31, 2025, down from $201.7M at Dec 31, 2024; runway projected into H2 2026.
- First patient dosed in Phase 2 LINNET study of lorigerlimab in platinum-resistant ovarian and clear cell gynecologic cancers.
- LORIKEET Phase 2 (lorigerlimab + docetaxel in mCRPC) clinical update expected in second half of 2025.

## SEC filing metadata
- accession: 0001125345-25-000054
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/0001125345-25-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/mgnx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-25-000054
- JSON: https://secwatch.observer/filing/0001125345-25-000054.json
- Plain text: https://secwatch.observer/filing/0001125345-25-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.